An immunotherapy drug called ‘pembrolizumab’ has been shown to significantly reduce disease recurrence in patients with the most aggressive type of breast cancer, according to results from a phase III clinical trial led.
Ahead of International Clinical Trials Day, we hear from those who worked tirelessly behind the scenes to make sure clinical trials at Barts Health ran efficiently and safely during the pandemic.